Only 4 of 14 diabetes performance measures adequate, ACP position paper says
The College's Performance Measurement Committee recently reviewed 14 current performance measures for diabetes that are relevant to internal medicine.
In a recent position paper, ACP's Performance Measurement Committee reviewed 14 current performance measures for diabetes that are relevant to internal medicine.
Only four of the measures were found to meet ACP's rigorous standards for appropriate use, high-quality evidence, and scientific acceptability: kidney health evaluation at the individual and group practice levels, HbA1c control at the health plan level, eye examination at the health plan level, and angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker therapy at the individual physician level.
The paper notes that no performance measures assess glycemic control in patients who do not improve after first-line treatments, and few evaluate appropriate pharmacologic treatment, although the College has developed a performance measure concept with the goal of increasing prescription rates for patients eligible for the newer pharmacologic agents. “Together, these recommendations aim to encourage implementers and developers to establish and test performance measures that will lead to improvement in health outcomes for patients with diabetes,” the paper said.
The position paper was published by Annals of Internal Medicine on May 6.